Plasma Therapy of COVID-19 in Severely Ill Patients

Inclusion Criteria: * Willing and able to provide written informed consent prior to performing study procedures or have a legally authorized representative available to do so. * Age ≥18 years * Evidence of SARS-CoV-2 infection by PCR test of naso-/oro-pharyngeal swab or tracheal aspirate sample within 14 days of randomization * Peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air or requiring supplemental oxygen, non-invasive or invasive mechanical ventilation at screening * Evidence of infiltrates on chest radiography * Females of childbearing age and males, must be willing to practice an effective contraceptive method or remain abstinent during the study period. Exclusion Criteria: * Participation in another clinical trial of anti-viral agent(s) for COVID-19 * Receipt of any anti-viral agent(s) with possible activity against SARS-CoV-2 \<24 hours prior to study drug administration \[1\] * Mechanically ventilated (including veno-venous (VV)-ECMO) ≥ 5 days * Severe multi-organ failure * History of prior reactions to transfusion blood products meeting definitive case definition criteria, at least severe severity, and probable or definite imputability per National Healthcare Safety Network (NHSN)/Centers for Disease Control and Prevention (CDC) criteria * Known Immunoglobulin A (IgA) deficiency * Females who are pregnant 1. Use of remdesivir as treatment for COVID-19 is permitted.